Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namilumab versus adalimumab imaging study in early rheumatoid arthritis
2014-002945-23Phase 2Completed
- Sponsor
- Takeda
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in rheumatoid arthritis (RA) comparing Namilumab with Adalimumab (2 arms). Primary endpoint: Change from baseline in MRI structural damage markers at Week 24. Started Nov 2014; status: completed.
02
Drugs
namilumabadalimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2014-002945-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002945-23.